EVOK Evoke Pharma Inc

Nasdaq evokepharma.com


$ 10.68 $ 0.01 (0.09 %)    

Thursday, 13-Nov-2025 15:59:57 EST
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 10.69
$ 10.68
$ 10.44 x 294
$ 10.80 x 5
-- - --
$ 1.94 - $ 10.79
51,595
na
18.41M
$ 0.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 05-13-2025 03-31-2025 10-Q
5 03-13-2025 12-31-2024 10-K
6 11-07-2024 09-30-2024 10-Q
7 08-13-2024 06-30-2024 10-Q
8 05-14-2024 03-31-2024 10-Q
9 03-14-2024 12-31-2023 10-K
10 11-09-2023 09-30-2023 10-Q
11 08-10-2023 06-30-2023 10-Q
12 05-15-2023 03-31-2023 10-Q
13 03-21-2023 12-31-2022 10-K
14 11-09-2022 09-30-2022 10-Q
15 08-10-2022 06-30-2022 10-Q
16 05-10-2022 03-31-2022 10-Q
17 03-08-2022 12-31-2021 10-K
18 11-10-2021 09-30-2021 10-Q
19 08-12-2021 06-30-2021 10-Q
20 05-12-2021 03-31-2021 10-Q
21 03-11-2021 12-31-2020 10-K
22 11-10-2020 09-30-2020 10-Q
23 08-06-2020 06-30-2020 10-Q
24 05-12-2020 03-31-2020 10-Q
25 03-12-2020 12-31-2019 10-K
26 11-07-2019 09-30-2019 10-Q
27 08-08-2019 06-30-2019 10-Q
28 05-08-2019 03-31-2019 10-Q
29 03-06-2019 12-31-2018 10-K
30 11-13-2018 09-30-2018 10-Q
31 08-09-2018 06-30-2018 10-Q
32 05-14-2018 03-31-2018 10-Q
33 03-07-2018 12-31-2017 10-K
34 11-14-2017 09-30-2017 10-Q
35 08-14-2017 06-30-2017 10-Q
36 05-15-2017 03-31-2017 10-Q
37 03-15-2017 12-31-2016 10-K
38 11-09-2016 09-30-2016 10-Q
39 08-15-2016 06-30-2016 10-Q
40 05-11-2016 03-31-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 evoke-pharma-q3-eps-045-inline-sales-4284m-miss-4326m-estimate

Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.45) per share which met the analyst consensus estimate. This is a 5...

 evoke-pharma-rockets-on-grabbing-140-premium-in-acquisition-deal

Evoke Pharma surges after QOL Medical announces $11 cash acquisition, a 140% premium, expected to close by the end of 2025.

 5-healthcare-stocks-on-fire-this-week

Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech &...

Core News & Articles

WMT: -4% | Walmart shares are trading lower following mixed Q2 financial results. APM: 69% | DiamiR's APOE Genotyping Test ...

 evoke-pharma-q2-eps-062-misses-030-estimate-sales-3752m-miss-3796m-estimate

Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.30...

 evoke-pharma-secures-new-us-patent-for-gimoti-nasal-spray-targeting-moderate-to-severe-gastroparesis

Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) ...

 evoke-pharma-evok-shares-skyrocket-on-new-patent-whats-going-on

Shares of Evoke Pharma are trading sharply higher Wednesday morning. The specialty pharma company received a U.S. Patent Office...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION